Illustration of Tenofovir's positive impact on patients with HBV undergoing chemotherapy.

Tenofovir vs. Lamivudine: New Hope for Hepatitis B Patients Undergoing Cancer Treatment?

Reese Marlowe monogram
Reese Marlowe in Health & Wellness October 2026 • 4 min read.

"Groundbreaking Research Reveals Potential for Improved Outcomes in High-Risk Patients Battling Both Cancer and Hepatitis B"


Cancer treatment can be a life-saving journey, but it often comes with its own set of challenges. For individuals battling both cancer and chronic Hepatitis B (HBV), the path can become even more complex. The immune-suppressing effects of chemotherapy can potentially reactivate HBV, leading to serious liver complications. However, a new study offers a beacon of hope, suggesting that a commonly used antiviral drug called Tenofovir may significantly improve outcomes for these patients.

The study, published in Blood, focused on patients with advanced-stage cancer and chronic HBV. Researchers compared the effectiveness of Tenofovir to Lamivudine, another antiviral drug. The results point towards Tenofovir as a potentially superior option, with the potential to prevent HBV reactivation and reduce the risk of related complications. This is particularly significant because it could improve the quality of life for many individuals undergoing cancer treatment.

This article delves into the details of this groundbreaking research, its implications, and what it means for patients and healthcare providers. We will explore the study's findings, discuss the benefits of Tenofovir, and examine the context of these findings within the broader landscape of cancer and HBV management.

AI Search Multiple angles on this topic

HBV's Continuing Global Impact

The WHO's Global hepatitis report 2026 describes viral hepatitis as a leading global health problem, despite the availability of an effective hepatitis B vaccine since the 1990s and effective antiviral treatments for chronic hepatitis B. The report also highlights the continuing need to meet 2030 global elimination targets. In the United States, the CDC's HepTracker provides hepatitis B case-surveillance and viral-hepatitis mortality data to help identify trends and monitor progress toward eliminating viral hepatitis as a public health threat.

Tenofovir Evidence and Uncertainty

Tenofovir disoproxil fumarate (TDF) is examined as a treatment for chronic hepatitis B, including in comparisons between TDF-based combination therapy and TDF monotherapy. The available study material says it remains unclear whether combination therapy produces better outcomes than TDF alone. Other cited research evaluates newer tenofovir formulations, including tenofovir alafenamide and tenofovir amibufenamide, through retrospective and real-world comparisons rather than establishing a single universally superior approach.

A Developing Treatment History

The treatment history of chronic hepatitis B has progressed from prevention through vaccination to the use of antiviral medicines, but the supplied material does not provide a detailed chronology of specific discoveries or milestones. Current therapies are therefore best understood as part of an evolving effort to control long-term infection. The historical record also remains distinct from the question of which antiviral is preferable during cancer treatment.

Understanding the Challenge: HBV Reactivation During Cancer Treatment

Illustration of Tenofovir's positive impact on patients with HBV undergoing chemotherapy.

Chemotherapy, a cornerstone of cancer treatment, works by weakening the body's immune system to target cancer cells. However, this also increases the risk of reactivating latent viruses, including HBV. When HBV is reactivated, it can cause liver inflammation, damage, and even liver failure. For patients with cancer, dealing with these additional complications can delay treatment, reduce its effectiveness, and worsen overall health.

The original study sought to investigate the use of antiviral prophylaxis to mitigate this risk, comparing two commonly used drugs: Tenofovir and Lamivudine. The study involved a cohort of patients undergoing chemotherapy for advanced-stage cancer, a particularly vulnerable population. Researchers meticulously tracked the outcomes of these patients, looking for evidence of HBV reactivation, liver damage, and treatment disruptions.

  • Increased Risk: Individuals with chronic HBV face a heightened risk of reactivation during chemotherapy.
  • Potential Complications: HBV reactivation can lead to liver damage, treatment delays, and decreased quality of life.
  • Prophylactic Measures: Antiviral drugs are frequently used to prevent HBV reactivation in high-risk patients.
AI Search Multiple angles on this topic

Current Evidence Landscape

The supplied material does not identify a specific recent review or study for this subsection. More broadly, evidence on tenofovir and lamivudine should be interpreted according to the population studied, the formulation evaluated, and the clinical outcome measured. The available information here is insufficient to make a source-grounded claim about a definitive latest research consensus.

Safety Trade-Offs Among Tenofovir Formulations

The 2026 comparison identifies renal toxicity and reduced bone mineral density as risks associated with TDF in chronic hepatitis B treatment. It reports that tenofovir alafenamide (TAF) is more stable in plasma, uses a 25 mg dose rather than TDF's 300 mg dose, and produces approximately 90% lower plasma tenofovir levels. A separate study notes that long-term prognosis and safety data for TAF, TDF, and entecavir in HBV-related acute-on-chronic liver failure had not previously been available globally, underscoring limits in the evidence base.

Limits of Direct Comparison

The supplied material does not contain a direct, source-specific comparison of tenofovir and lamivudine for patients undergoing cancer treatment. Comparisons among antiviral medicines can be affected by differences in formulation, patient population, treatment history, and measured outcomes. Any conclusion about superiority between tenofovir and lamivudine would therefore require evidence not included in this subsection's source list.

The research demonstrated compelling evidence that Tenofovir might offer a more effective shield against HBV reactivation compared to Lamivudine. This suggests that Tenofovir might significantly improve outcomes for patients with cancer and HBV. The study also highlights the importance of proactive antiviral strategies in managing the intersection of cancer and viral infections.

A Promising Future for Patients

The findings from this study are a positive step forward, providing important new insights into the management of patients facing the dual challenges of cancer and chronic HBV. As research continues and clinical practices evolve, the potential of Tenofovir and similar treatments promises to provide improved care and a better quality of life for those navigating the complexities of both conditions. The study's outcomes provide an important step forward, providing hope and direction for the future of cancer care.

AI Search Multiple angles on this topic

An Evidence-Led Choice

The supplied material does not provide an expert commentary that directly resolves whether tenofovir or lamivudine is preferable during cancer treatment. A careful synthesis would need to weigh antiviral effectiveness against safety considerations and the evidence available for the relevant patient population. The source set here does not support declaring one drug universally superior.

Toward New HBV Therapies

A 2025 horizon-scanning review describes chronic hepatitis B as affecting over 254 million people and emphasizes the limited curative potential of current therapies. Its focus is emerging trends and future directions in novel anti-HBV therapeutics. Current research also includes a 96-week retrospective two-center study of TAF in HBeAg-positive and HBeAg-negative patients aged over 30 years with normal ALT and detectable HBV DNA, while treatment goals remain permanent suppression of HBV replication to prevent decompensation, cirrhosis, and hepatocellular carcinoma.

Contested Outcomes and Global Burden

The comparative effectiveness of tenofovir versus entecavir in preventing hepatocellular carcinoma among people with chronic hepatitis B remains controversial, according to the 2025 study summary. Other research is examining how TDF affects intrahepatic viral burden and the liver immune microenvironment, areas in which the impact of nucleos(t)ide analogues is described as unclear. Real-world work on tenofovir amibufenamide further reflects the broader challenge of evaluating effective and safe long-term therapies for a major global health problem.

Evidence From Clinical Practice

Real-world studies are evaluating tenofovir amibufenamide in people with chronic hepatitis B, including a reported cohort of 186 patients in one clinical study. Another real-world pharmacological assessment examines tenofovir amibufenamide and its comparison with tenofovir alafenamide. These studies aim to inform subsequent antiviral selection, but the supplied material does not establish how their findings apply specifically to patients receiving cancer treatment or to comparisons with lamivudine.

Prevention results against their comparison groups

  • Tenofovir OR 0.00; lamivudine OR 0.10In a network meta-analysis, tenofovir prophylaxis had an odds ratio of 0.00 for HBV reactivation versus no prophylaxis (95% CI 0.00–0.04); lamivudine had an odds ratio of 0.10 (95% CI 0.06–0.14).[1]
  • 0.6% vs 20%; 0% vs 40%; 4.5% vs 100%In a comparison with historical controls, patients receiving nucleos(t)ide analogue prophylaxis had lower rates of liver decompensation (0.6% vs 20%), chemotherapy interruption (0% vs 40%), and hepatitis (4.5% vs 100%).[2]

What the prevention comparisons establish

Taken together, the comparisons indicate that antiviral prophylaxis can reduce HBV-related complications during cancer treatment relative to no prophylaxis or historical controls. They do not establish that tenofovir is better than lamivudine in a direct comparison: the lamivudine comparison here is with entecavir, while the network analysis compares treatments across its evidence base.[1] [2] [3]

The TDF result is a comparison with close monitoring in a particular group with resolved HBV receiving rituximab, not a direct comparison with lamivudine or evidence for every cancer-treatment population.[4]

How the evidence differs by comparison and risk

Earlier literature reported chemotherapy-associated reactivation rates as high as 88%, and linked resulting treatment delays or early termination with lower cancer-patient survival. This gives clinical context for why preventing reactivation matters, but it is not an estimate of outcomes in the comparisons above.[5]

Lamivudine resistance was reported in two cases during immunosuppressive therapy, with potentially severe consequences. The report signals a possible vulnerability, but those cases alone do not quantify how often resistance occurs.[6]

The cited definition counts chemotherapy disruption as premature termination or a delay of at least seven days between cycles due to reactivation or related hepatitis. This makes disruption a treatment-process outcome, distinct from the viral and liver outcomes.[5]

Risk is not uniform: high baseline HBV DNA is identified as a predictor of reactivation, while high viral load, cirrhosis, rituximab, and distant metastasis are associated with prophylaxis failure or withdrawal hepatitis. These factors complicate comparisons across patient groups.[7] [8]

What remains unresolved about antiviral choice

  • How much do baseline viral load, cirrhosis, rituximab exposure, and distant metastasis change the likelihood of prophylaxis failure across treatment groups?[8]

Sources

  1. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation (pmc.ncbi.nlm.nih.gov)
  2. Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy. (pubmed.ncbi.nlm.nih.gov)
  3. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. (pubmed.ncbi.nlm.nih.gov)
  4. synapse.koreamed.org (synapse.koreamed.org)
  5. Efficacy of nucleos(t)ide analogues(NAs) in preventing virus reactivation in oncology patients with HBV infection after chemotherapy or surgery: A network meta-analysis (pmc.ncbi.nlm.nih.gov)
  6. Death from Liver Failure despite Lamivudine Prophylaxis during R-CHOP Chemotherapy due to Rapid Emergence M204 Mutations (pmc.ncbi.nlm.nih.gov)
  7. A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy (pmc.ncbi.nlm.nih.gov)
  8. Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy. (pubmed.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

Why are cancer patients with Hepatitis B at a higher risk during chemotherapy?

Cancer patients undergoing chemotherapy are at a higher risk because chemotherapy weakens the immune system. This immunosuppression can reactivate the Hepatitis B virus (HBV) in individuals with chronic HBV, leading to liver inflammation, damage, and potential liver failure. Managing HBV reactivation during cancer treatment can also delay cancer treatment and reduce its effectiveness.

2

What is the significance of using antiviral drugs like Tenofovir during cancer treatment for patients with Hepatitis B?

Antiviral drugs like Tenofovir are crucial for preventing Hepatitis B virus (HBV) reactivation in cancer patients undergoing chemotherapy. Reactivation can lead to severe liver complications, disrupting cancer treatment and worsening overall health. Prophylactic use of Tenofovir can mitigate these risks, potentially improving the quality of life and treatment outcomes for these patients. While the study focuses on Tenofovir and Lamivudine, other antiviral medications may also play a role, but were not specifically discussed.

3

How does Tenofovir compare to Lamivudine in preventing Hepatitis B reactivation in cancer patients?

A recent study suggests that Tenofovir may be more effective than Lamivudine in preventing Hepatitis B virus (HBV) reactivation in cancer patients undergoing chemotherapy. The research indicated that Tenofovir offers a potentially superior shield against HBV reactivation, which could lead to significantly improved outcomes for patients battling both cancer and HBV. Further research may be needed to confirm these findings and explore the specific mechanisms behind the difference in effectiveness between Tenofovir and Lamivudine.

4

What are the potential long-term implications of using Tenofovir to manage Hepatitis B reactivation during cancer treatment?

The long-term implications of using Tenofovir to manage Hepatitis B virus (HBV) reactivation during cancer treatment include potentially reducing the risk of liver damage and improving the overall survival rates for patients with both conditions. Effective prevention of HBV reactivation can also lead to fewer treatment delays and disruptions, allowing patients to complete their cancer therapy more successfully. Moreover, improved quality of life due to fewer HBV-related complications is a significant benefit. Future studies could explore the long-term impact on liver health and the development of antiviral resistance.

5

What specific advancements might we see in clinical practice as a result of studies focusing on Tenofovir and Hepatitis B reactivation during cancer treatment?

As a result of studies focusing on Tenofovir and Hepatitis B virus (HBV) reactivation during cancer treatment, clinical practice may see more widespread adoption of proactive antiviral strategies, particularly the use of Tenofovir, for patients at high risk of HBV reactivation. There might be enhanced screening protocols to identify HBV-positive cancer patients early, enabling timely intervention. Furthermore, guidelines for managing HBV reactivation may be refined, incorporating the latest research on antiviral effectiveness and patient outcomes. These advancements could lead to improved care coordination between oncologists and hepatologists, resulting in better overall management of these complex cases. Future studies might also explore personalized treatment approaches based on individual risk factors and HBV viral load.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.